Donny Wong Ph.D., principal analyst at Decision Resources, is available to discuss diabetes-related findings that will be announced during the American Diabetes Association's 68th Scientific Sessions being held June 6-10, 2008 in San Francisco.

  Dr. Wong can discuss:    -- General questions about the size and scope of the pharmaceutical market      for diabetes therapies and the market impact of the following emerging      drug classes: SGLT-2 inhibitors, DPP-IV inhibitors and GLP-1 analogues   -- Presentations at the ADA conference of the full reports from the      following clinical trials: the ACCORD Study, the ADVANCE Study and the      VA Diabetes Trial.   -- The market potential for novel non-injectable insulin formulations that      remain in development following the suspension of development of      inhaled insulins by Eli Lilly and Novo Nordisk   -- The ongoing impact on the sales of Avandia following the publication of      a meta-analysis that questions the cardiovascular safety of the drug   -- The recent filing by Novo Nordisk for regulatory approval in the United      States and Europe of liraglutide for the treatment of type 2 diabetes   

To speak with Dr. Wong, please contact Liz Marshall at 781-296-2563 or emarshall@dresources.com.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   781-296-2563   emarshall@dresources.com 

PRNewswire -- June 4

SOURCE: Decision Resources

Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent Through 2012

View Now